|Bid||0.00 x 1000|
|Ask||0.00 x 1400|
|Day's Range||186.33 - 187.88|
|52 Week Range||150.37 - 234.26|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||10.66|
|Earnings Date||Jun 28, 2019|
|Forward Dividend & Yield||3.00 (1.42%)|
|1y Target Est||221.64|
Blackspark Capitol CEO Jose Barrionuevo talks to Yahoo Finance to discuss the implications of the U.S. and Mexico agreement.
Kroger (KR) is making investments to expand grocery offerings and e-commerce presence. However, incremental investments may keep margins under pressure.
Boston Beer (SAM) gains from momentum in shipment volume and depletion, driven by its three-point growth plan. This places it ahead of peers in an otherwise struggling alcohol industry.
Which stock wins in a battle between the biggest cannabis producer by market cap and the biggest supplier to the cannabis industry?
If you want to know who really controls Constellation Brands, Inc. (NYSE:STZ), then you'll have to look at the makeup...
Constellation Brands Inc NYSE:STZView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for STZ with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold STZ had net inflows of $7.11 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. STZ credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Constellation Brands (STZ) closed at $189.18 in the latest trading session, marking a -0.07% move from the prior day.
AB InBev (BUD) keeps the momentum alive on robust sales trend, growth of global brands and strong forward outlook. Additionally, the recent lifting of aluminum tariffs is likely to aid performance.
Broader markets received somewhat of a shock to the system in early May when President Trump announced that the U.S.-China trade dispute was far from being resolved any time soon. And many sectors have been choppy in the fast few weeks. One stock that has been in a downtrend since late April is Canada-based Canopy Growth (NYSE:CGC), a front-runner of the marijuana industry (MI).Source: Shutterstock As pot stocks are giving back some of their big gains from the last 12 months, it's quite hard to predict which stocks in the industry will perform well in this volatile market. CGC stock is expected to release Q4 fiscal 2019 earnings on June 20. Last quarter saw CGC's earnings come in significantly below expectations. And the stock is seeing weakness after a strong start to the year. Now that the reporting season is fast approaching, let's look at what may be next for the Canopy Growth stock price. Long-Term Tailwinds for Canopy Growth StockAs a diversified cannabis and hemp company, Canopy Growth is Canada's largest pot stock by revenue and market cap. It started trading on the Toronto Stock Exchange (TSE) in August 2016 and got a dual listing at the New York Stock Exchange in May 2018.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 A-Rated Stocks to Buy Under $10 The global legal marijuana market size is expected to be over $65 billion by the end of 2025. Yet at present, the legalized MI is still at its infancy in Canada and almost non-existent globally. In December 2018, marijuana producers and investors cheered when the U.S. legalized hemp and hemp-derived ingredient cannabidiol (CBD), the non-psychoactive ingredient of marijuana.CBD is especially popular among consumers seeking relief from physical pain as many believe that CBD provides most of the health benefits of medical marijuana. Because hemp is now an ordinary agricultural commodity, Canopy Growth has obtained a license to process and produce hemp products in New York State.Canopy Growth is hoping become one of the first marijuana producers to have its products in the U.S. market through its partnership with the NY state-headquartered alcoholic beverages giant Constellation Brands (NYSE:STZ) which has already invested $4 billion into CGC stock.The two companies are currently developing cannabis-infused beverages for Canada, where experts believe they will be legal by 2020. This legalization of edibles is likely to act as a powerful catalyst for the major cannabis companies.Although it is too soon to predict how the legal hemp production in the U.S. will affect CGC's bottom line, Canadian leaders like Canopy Growth are likely to become the first ones to be positively affected by major North American or global developments that may boost the sales and the use of recreational or medicinal marijuana. This, in turn, would also boost the stock price of CGC.However, it will probably be several quarters before the U.S.-related investments would pay off and turn into profits. Short-Term Headwinds for CGCMany investors are worried that the initial hype surrounding the industry may possibly be decreasing. Therefore, CGC's upcoming earnings report will be important not just for the company but also for the industry, as not everyone is convinced that Canadian recreational weed sales will remain strong.And if CGC's numbers do not come out as high as expected, then there would not be much momentum for Canopy Growth stock or the cash-intensive industry as a whole. Investors are beginning to get concerned about how increased spending is reducing earnings and cash flow numbers. So far, cannabis stocks have largely been driven by hype and publicity, such as the investment by Constellation Brands in CGC.Indeed, many analysts are concerned that the valuations in this new consumer market are extremely high, that most of the cannabis stocks are going through cash fast and that many are not likely to achieve profitability in the near future.In January, CEO Bruce Linton said that Canopy Growth did not plan to acquire any more Canadian cannabis assets. In other words, the company is possibly regarding the growth levels in Canada as not enough for the ambitious expansion plans.If further growth does not come from the rest of the world and especially the U.S., Wall Street is likely to start devaluing most of these pot companies substantially. Thus, if there were legal issues, especially in the U.S., regarding the potential of legalization of marijuana at the federal level, the industry would take a hit.One important benefit of the investment by STZ, which now has a 37% interest in CGC, has been that Canopy Growth has the financial muscle to pursue acquisitions and invest in R&D to grow its production space. However, not all potential deals are likely to benefit CGC shareholders immediately.For example, the group has an agreement in place to acquire U.S.-based Acreage Holdings (OTCMKTS:ACRGF) for $3.4 billion. However, this acquisition can only happen if cannabis is legalized federally in the U.S. Would investors give Canopy Growth a blank check for an open-dated deal? Takeaway for Canopy Growth StockInvestors may have to wait until Canopy Growth's earnings report later in the month to have a better view on the developments in the industry as they affect CGC stock. Analysts will pay special attention to the sales figures and the level of operational loss.For Canopy Growth stock, it may be a long and choppy journey back to the all-time high of $59.25 as rich valuations in this commodity-based consumer market may take a hit in the coming months.There might also be profit taking and investor uncertainty about the general markets as well as the weed industry. As we enter the second half of the year, could investors become more risk averse and shy away from these high-growth yet potentially risky stocks for their portfolios?In addition, investors who look at the CGC stock chart may be raising their eyebrows as currently the stock is down from a 2019-high of $52.74 reached on Apr. 29 to low-$40's.Those who bought at the high might not be too happy, but investors who had the courage to step in at the end of 2018 when CGC stock saw $25.26 are still in pretty good shape. If you are an investor with paper profits, should you consider locking in some of those gains now?At present, the short-term technical charts, especially the trend lines and support and resistance levels, are telling investors to exercise caution.Of course, Canopy Growth stock may initially rally around the quarterly report, and a potential investor could miss out on some profits for not having bought into the CGC shares early on. Or there might be a few other newsworthy moments that may get investors to set their sights back on Canopy Growth stock. However, I do not think such potential up moves will be long-lived. * 7 Stocks to Buy As They Hit 52-Week Lows If you are considering investing in Canopy Growth, you may want to start building a position between the $27.5-$32.5 levels, and expect to hold the stock for several years. In the meantime, expect a lot of volatility in CGC share price.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy As They Hit 52-Week Lows * 4 Antitrust Tech Stocks to Keep an Eye On * 5 Gold and Silver Stocks Touching Intraday Highs Compare Brokers The post CGC Stock Will Be Volatile Heading Into Earnings appeared first on InvestorPlace.
In a crowded crop of cannabis stocks Canopy Growth (NYSE:CGC) remains a favorite among analysts for more than a few good reasons. But the the price chart still suggests CGC stock isn't ready for picking. In fact, the stock could grow into a very profitable shorting opportunity. Let me explain.Source: Shutterstock Shares of Canopy Growth seemingly have everything going for it. The latest to promote that fact is investment firm Stifel. Analyst W. Andrew Carter initiated shares Thursday with a buy rating and price target of CAD $64 or an equivalent $47.77 USD for the NYSE-listed shares. At the same time CGC stock was hailed as the "best investable opportunity" in cannabis.Behind the bullish-sounding praise, Mr. Carter pointed out Canopy's best-in-breed leadership and large-scale infrastructure in Canada. The company's partnership with Constellation Brands (NYSE:STZ), Canopy's multiple channels to profit from the U.S. market and its top-notch positioning for cashing in on global medicinal opportunities were also noted.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets The problem with the approval is there's nothing new under the sun here. Stifel's recommendation states the obvious to anyone with more than a passing interest in CGC stock over the past year. Further, given a meager sub $48 price target, which barely compensates investors for the week-to-week risk in owning a volatile name like CGC stock, growing your dollars from a CGC stock purchase today continues to look like tough business on the price chart. CGC Stock Daily Chart Click to EnlargeCanopy's impressive credentials on paper continues to be at odds with a volatile price chart and one with a knack for temperamental behavior. A recent warning in mid-May to simply watch CGC from the sidelines was a good call as shares went on to shed roughly 15% at their recent lows. And I don't see that pain as being over just yet either.This week's rally has reclaimed some of that lost value. The bad news is CGC stock is now stationed beneath the 200-day simple moving average after breaking the key long-term and closely-watched trend line. Moreover, the move higher this week has formed a bearish flag whose low undercut a similar failed pattern from April, which incidentally found support off the same moving average.The technical interpretation is this time bulls won't be so lucky with the current bearish pattern given the extra layer of resistance. If I'm correct, Canopy Growth shares will also be in position for a much larger correction towards the December low.For traders agreeable with this bearish outlook, I'd recommend shorting shares below $41. The modified entry is about 1% beneath Thursday's doji closing print and should help trigger some bearish momentum out of the flag. The short is also contingent on Canopy Growth remaining below $43.50. This line in the sand allows for a necessary couple percent of wiggle room above the 200 SMA. Given Canopy Growth stock's history of erratic and volatile price behavior, that's sensible enough. Better yet, it also keeps this bearish play from getting smoked off and on the price chart.Disclosure: Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy As They Hit 52-Week Lows * 4 Antitrust Tech Stocks to Keep an Eye On * 5 Gold and Silver Stocks Touching Intraday Highs Compare Brokers The post Why Canopy Growth Stock Is the Perfect Pick for a Short appeared first on InvestorPlace.
Casey's (CASY) remains on track with its value creation plan. Further, the company's price and product optimization strategy will help augment sales in the final quarter of fiscal 2019.
When I was asked to opine about Canopy Growth (NYSE: CGC) stock, I vowed to myself to resist the temptation to make weed-related puns, other than to note that expectations for the Canadian company are "sky high," meaning a bit nutty.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsI don't know how else to describe an unprofitable company with a history of earnings misses that has managed to rocket 57% since the start of the year, outperforming the S&P 500. which rose 13% during that same time period. * 7 Stocks to Buy As They Hit 52-Week Lows The Smokin' Hot Returns of Canopy StockWall Street analysts have an average price target on CGC stock of $58.53, almost 40% higher than where CGC stock price closed Friday, even though analysts don't expect the company to be consistently profitable until 2021, despite the $4 billion investment it got from Constellation Brands (NYSE:STZ) last year.There are many red flags for skeptics on CGC stock to focus on. Among these red flags are the 26 acquisitions and eight financing deals the company has done in less than five years, which is a lot of deals for a company that was founded in 2009. The Mother of All Growth SpurtsI can't imagine the difficulty of growing CGC's workforce from 156 in 2015 to more than 2,700 as of the most recent quarter or of keeping a watch on its surging R&D expenses, which were $3 million in the latest quarter versus $500,000 a year earlier.Even so, I am not going to trash CGC stock because I may one day be able to benefit from the products the company makes to treat Parkinson's Disease, which I have. Parkinson's is the second-most common neurological disease behind Alzheimer's. My Personal Interest in CGC StockOn Facebook, I have seen videos of my fellow Parkinson's victims whose symptoms seem to disappear after taking cannabidiol or CBD, a compound derived from cannabis that lacks the THC which makes users high. I am not sure who is behind the posts or how long the relief lasts. Fortunately, my Parkinson's hasn't progressed as far the people in the videos I saw, though I worry that it might someday. Since I am not a doctor, I will refrain from speculating about the scientific issues at play here. I am taking the wait-and-see approach to CBD advocated by The Michael J. Fox Foundation because results of scientific studies on the topic have yielded mixed results. CBD has proven to be beneficial in treating some forms of epilepsy and may prove to have some efficacy when it comes to treating anxiety. Unfortunately, some CBD companies are making irresponsible claims that the compound can cure cancer. Quality Control ProblemOf course, scientists have been reluctant to study the health benefits of cannabis since it remains illegal under U.S. federal law. Another one of the weaknesses of the CBD market is quality control, which Canopy is in a position to address thanks to its recently announced $150 million hemp processing plant that it plans to build in New York State. The Bottom Line on Canopy Growth StockInvestors with a high tolerance for risk should buy Canopy stock, but do me a favor and make your decision before indulging in the company's non-CBD products.As of this writing, Jonathan Berr doesn't own any shares of any companies discussed in this post. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage Compare Brokers The post My Interest in Canopy Growth Stock Goes Beyond Its Price appeared first on InvestorPlace.
Cannabis stocks were mostly higher Friday, rising with the broader market after a weaker-than-expected May jobs report bolstered expectations that the Federal Reserve will cut interest rates sooner rather than later.
How do we determine whether Constellation Brands, Inc. (NYSE:STZ) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Cannabis stocks were mostly lower Thursday, resuming the selloff seen earlier in the week, as investors shrugged off a buy recommendation on market leader Canopy Growth Corp., and news that Delaware is closer to adult-use legalization.